BALTIMORE, Aug. 26, 2010 (GLOBE NEWSWIRE) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has published a research update on Radient Pharmaceuticals Corporation (NYSE Amex:RPC), a leading in-vitro diagnostics test kits provider, with a focus on the oncology/cancer segment.
Radient has won FDA approval for its lead product as a post-surgery colorectal cancer monitoring test and is the only approved product in key markets abroad as a general cancer screen. As part of its diagnostics focus, Radient is in the midst of monetizing non-core assets and business lines through divestitures and out-licensing.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines milestone events that he believes will serve as catalysts for the Company's shares.
"Radient is well-positioned to lead the global charge in a $1 billion market for a general cancer screen test kit, which could potentially save lives and substantial sums of money otherwise used for treatment. We view Radient as a stock that offers great value and potential for its existing operations, hidden but soon-to-be monetized value in its non-core assets, and home run potential with its cancer screen platform. A steady stream of news and events in the coming months should serve as catalysts for the stock," Goldman commented.
To view a summary of the report or download the report in its entirety, please visit www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap stock market research reports and weekly newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer. To download our research and disclosures, or for more information, visit www.goldmanresearch.com.
About Radient Pharmaceuticals Corporation.: Radient Pharmaceuticals Corporation (NYSE Amex:RPC) is an integrated In-Vitro Diagnostic (IVD) firm devoted to the research, development, manufacturing, and marketing of diagnostic test kits. Radient's primary focus is on the cancer/oncology diagnostic segment, with its lead product, Onko-Sure™. Onko-Sure™ is a proprietary IVD cancer test that has been shown to detect or monitor over 15 various types of early stage cancer. Onko-Sure™ is currently approved by the U.S. FDA as a colorectal cancer monitoring test. Onko-Sure™ is also approved for sale in Canada as a lung cancer screen test, and in Europe and several Asian nations as a general cancer screen. Radient has significant assets in China and owns 100% of a proprietary cancer vaccine therapy technology.
For more information and disclosures, visit www.radient-pharma.com.